COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest peer-reviewed research articles from the Eastern Mediterranean Region
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean
COVID-19 | Discover the latest publications published by WHO Regional Office for the Eastern Mediterranean

Virtual Health Sciences Library

  • Home
  • Search
  • Knowledge Base
  • Get a journal indexed in the Index Medicus
  • MyVHSL
  1. Home
  2. IMEMR
  3. Search Result
  4. Vaginal micronized progesterone capsule versus vaginal progesterone gel for luteal support in normoresponder IVF/ICSI-ET cycles

Vaginal micronized progesterone capsule versus vaginal progesterone gel for luteal support in normoresponder IVF/ICSI-ET cycles

Authors

Sofuoglu Kenan
Gun, Ismet
Sahin, Sadik
Ozden, Okan
Tosun, Oktay
Eroglu, Mustafa
Zeynep Kamil Training and Education Hospital ; , Department of Obstetrics and Gynecology ;

Pak. J. Med. Sci. 2015; 31 (2): 314-319
Pakistan Journal of Medical Sciences
Journal Country: Pakistan
P-ISSN: 1682-024X
E-ISSN: 1681-715X
Type of Publication: Journal Article
Category: Humans, Female,
Type of Research: Clinical
Keywords: Progesterone
Broad Subjects: Maternal, Reproductive and Child Health, Capsules ,Gels ,Fertilization in Vitro ,Sperm Injections, Intracytoplasmic ,Luteal Phase ,Retrospective Studies
Citation: Kenan Sofuoglu ,Ismet Gun ,Sadik Sahin ,Okan Ozden ,Oktay Tosun ,Mustafa Eroglu , Vaginal micronized progesterone capsule versus vaginal progesterone gel for luteal support in normoresponder IVF/ICSI-ET cycles, Pak. J. Med. Sci. 2015; 31 (2): 314-319

Abstract English

To compare the outcomes of luteal phase support by micronized progesteron vaginal capsule 600mg/day and progesterone vaginal gel 180 mg/day in the normoresponder IVF/ICSI-ET cycles of the patients down-regulated via GnRH agonist long protocol or fixed antagonist protocol below 40 years of age. A total of 463 normoresponder cycles between January 2013 and December 2013 were retrospectively analyzed. Those with a BMI>28 kg/m [2] , any kind of uterine, ovarian or adnexial pathology, any significant systemic, endocrine or metabolic disease or who were reported as azoospermia, were excluded from the study. The patients were grouped according to the usage of micronized progesterone vaginal capsule 600 mg/day [Group 1] or progesterone vaginal gel 180 mg/day [Group 2] as luteal phase Treatment cycle characteristics and pregnancy outcomes were compared between groups. Group-I included 220 cycles and group 2 included 243 cycles. Although the MII oocyte percentage among the total number of MII oocytes was significantly higher in Group-II [77.5% and 80.2%; p=0.034] , positive beta-hCG [32.3% and 21.8%; p=0.015] and clinical pregnancy [27.3% and 17.7%; p=0.018] rates were significantly higher in Group-I. No difference was observed between groups regarding the ongoing pregnancy rates [23.2% and 17.3%; p=0.143] . Micronized progesterone vaginal capsule 600 mg daily used for luteal support in the IVF/ICSIET cycles was observed to significantly increase the biochemical and clinical pregnancy rates compared to progesterone vaginal gel 180 mg daily. However, no difference was observed between two groups regarding ongoing pregnancy rates

Full Text English

Subscribe to VHSL Newsletters

© 2020 WHO – EMRO